AKR1C3 and hepatocellular carcinoma: AKR1C3 has also been observed to regulate lipid droplet formation in HCC, consequently contributing to sorafenib resistance, while its inhibition rapidly induces mitochondrial fission and apoptosis, implying AKR1C3 as a promising therapeutic target in HCC [16].